Huma receives the first and only multi-condition regulatory approval under EU MDR Class IIb for its configurable SaMD platform for disease management

Huma Therapeutics (“Huma”), a global leader in the digital health sector, announced today that it has become the only company in the world to receive EU MDR 2017/745 Class IIb certification for a Software as Medical Device (SaMD). This level of regulatory certification makes Huma’s technology the configurable, agnostic platform with the highest classification in the industry today.